# US 9,434,716 B2 · Antigen binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,716 B2
- Document ID: US9434716B2
- Status: Granted
- Kind: B2
- Application number: 13/037,505
- Filed: 2011-03-01
- Published: 2012-09-06
- Granted: 2016-09-06
- Earliest claimed: 2011-03-01
- Assignees: Glaxo Group Limited
- Applicants: Tejinder Kaur Bhinder; Susannah Karen Ford; Volker Germaschewski; Alan Peter Lewis; Mark Brian Pepys
- Inventors: Tejinder Kaur Bhinder; Susannah Karen Ford; Volker Germaschewski; Alan Peter Lewis; Mark Brian Pepys
- Web page: https://patentgrep.com/patent/US9434716B2

## CPC

- C07K 16/18: against material from animals or humans
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

## Claims

### Claim 1

A humanised antibody, comprising SEQ ID NO:1 (CDRH1), SEQ ID NO:2 (CDRH2), SEQ ID NO:3 (CDRH3), SEQ ID NO:4 (CDRL1), SEQ ID NO:5 (CDRL2), and SEQ ID NO:6 (CDRL3), which binds to serum amyloid P component (SAP).

### Claim 2

A humanised antibody, which specifically binds to SAP and comprises a heavy chain variable region as shown in SEQ ID NO:28; and a light chain variable region as shown in SEQ ID NO:35.

### Claim 3

A humanised antibody, which specifically binds to SAP and comprises a heavy chain as shown in SEQ ID NO:62; and a light chain as shown in SEQ ID NO:64.

### Claim 4 (depends on 1, 2)

The humanised antibody as claimed in any one of claims 1, 2, or 3, wherein the SAP is human SAP which is bound to amyloid fibrils in vivo.

### Claim 5 (depends on 1, 2)

The humanised antibody as claimed in any one of claims 1, 2, or 3, wherein the humanised antibody binds to the A face of human SAP.

### Claim 6 (depends on 1, 2)

The humanised antibody as claimed in any one of claims 1, 2, or 3, wherein the humanised antibody activates the human complement system.

### Claim 7 (depends on 1, 2)

The humanised antibody according to claims 1, 2, or 3, wherein the humanised antibody comprises a human IgG1 or IgG3 human constant domain.

### Claim 8 (depends on 1, 2)

A pharmaceutical composition comprising a humanised antibody as defined in any one of claims 1, 2, or 3 and a pharmaceutically acceptable carrier.